Webdisclosure.com

Search

UCB (EBR:UCB) UCB Media Room - Notice of Early Redemption

Directive transparence : information réglementée

14/04/2021 07:04
https://mb.cision.com/Public/18595/3324684/bddc8698a06a8522_800x800ar.jpg ** Notice of Early Redemption - =E2=82=AC350 million =E2=82=AC 1.875% fixed= rate notes due 2 April 2022 ------------------------------------------------------------ Brussels (Belgium), 14 April 2021 =E2=80=93 07.00 am (CEST) =E2=80=93 regul= ated information - UCB SA/NV announces its intention to redeem the =E2=82= =AC350,000,000 1.875 per cent fixed rate notes due 2 April 2022 (the "Notes= ") in whole in accordance with the Condition 5(d) of the Prospectus (Redemp= tion at the Option of the Issuer (Issuer Call)). UCB takes this action in t= he context of its active liability management. The Notes will be redeemed on 29 April 2021 (the "Optional Redemption Date"= ) at their Optional Redemption Amount together with any accrued and unpaid = interest up to, but excluding, the Optional Redemption Date. The Optional Redemption Amount, calculated by the Calculation Agent on the = basis of the Reference Rate on 12 April 2021 at 11.00 am, is 101.90451% of = the Calculation Amount (=E2=82=AC100,000). The accrued and unpaid interest = is 0.13870% of the Calculation Amount. This notice is irrevocable and shall be governed by Belgian law. Further information This press release and the prospectus dated 10 March 2015, in relation with= the issue of =E2=82=AC350,000,000 1.875 per cent fixed rate notes due 2 Ap= ril 2022, are available on UCB=C2=A0SA/NV=E2=80=99s website via the followi= ng link (https://www.ucb.com/investors/UCB-financials) . Contact information Antje Witte, Investor Relations, UCB T +32 2 559 94 14, antje.witte@ucb.com About UCB UCB, Brussels, Belgium (www.ucb.com (http://www.ucb.com/) ) is a global bio= pharmaceutical company focused on the discovery and development of innovati= ve medicines and solutions to transform the lives of people living with sev= ere diseases of the immune system or of the central nervous system. With ap= proximately 8 400 people in nearly 40 countries, the company generated reve= nue of =E2=82=AC 5.3 billion in 2020. UCB is listed on Euronext Brussels (s= ymbol: UCB). Follow us on Twitter: @UCB_news GenericFile UCB EUR 350m 2022 eurobond - Issuer Call - press release - 14 April 2021 - = NED (https://mb.cision.com/Public/18595/3324684/a65d4453f6627d28.pdf) Gener= icFile UCB EUR 350m 2022 eurobond - Issuer Call - press release - 14 April 2021 - = ENG (https://mb.cision.com/Public/18595/3324684/b69ffcf5bafa16af.pdf) Gener= icFile UCB EUR 350m 2022 eurobond - Issuer Call - press release - 14 April 2021 - = FRA (https://mb.cision.com/Public/18595/3324684/bfcebddf2c69e29c.pdf)=0D =0D ______________________=0D If you would rather not receive future communications from UCB SA, please g= o to https://eu.vocuspr.com/OptOut.aspx?2973226x20421x66400x1x6868579x24000= x6&Email=3Dregnews%40symexglobal.com.=0D UCB SA, All=C3=A9e de la Recherche, 60 ., Brussels, . B - 1070 Belgium=